LA JOLLA, Calif. (December 6, 2022) — Calidi Biotherapeutics, Inc. (Calidi), a
clinical-stage biotechnology company that is pioneering allogeneic
cell-based platforms to revolutionize oncolytic virus therapies, today
announced an upcoming presentation at the 7th Annual Oncolytic Virotherapy
Summit, taking place in Boston, Massachusetts and virtually,
December 6-8, 2022.
Details of the presentation are below:
Title: Allogeneic Stem Cell-Based Platforms
to Potentiate and Deliver Oncolytic Virus Therapies
Date: Thursday
December 8th, 2022, 10:00 a.m. ET
Presenter: Boris
Minev M.D., President, Medical & Scientific Affairs, Calidi
Biotherapeutics
About Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage immuno-oncology company
with proprietary technology that is revolutionizing the effective delivery
and potentiation of oncolytic viruses for targeted therapy against
difficult-to-treat cancers. Calidi Biotherapeutics is advancing a
potent allogeneic stem cell and oncolytic virus combination for use in
multiple oncology indications. Calidi’s off-the-shelf, universal
cell-based delivery platforms are designed to protect, amplify, and
potentiate oncolytic viruses currently in development leading to enhanced
efficacy and improved patient safety. Calidi Biotherapeutics is
headquartered in La Jolla, California. For more
information, please visit www.calidibio.com.
Forward-Looking Statements
This press release may contain forward-looking statements and
information relating to, among other things, Calidi Biotherapeutics and
its business plan and strategy, and the highly competitive
pharmaceutical industry. These forward-looking statements are based
on the beliefs of, assumptions made by, and information currently
available to the Company. When used in this press release, the
words “estimate,” “project,”
“believe,” “anticipate,” “intend,”
“expect” as well as similar terms, are forward-looking in
nature. These forward-looking statements involve a number of risks,
uncertainties (many of which are beyond Calidi’s control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date on which they are made. Calidi Biotherapeutics does not
undertake any obligation to revise or update these forward-looking
statements to reflect events or circumstances after such date or to
reflect the occurrence of unanticipated events.
For Partnering Opportunities, or to schedule a meeting with
Calidi Biotherapeutics during the conference:
David
Sans, FAARM, Ph.D., MBA
Chief Corporate Development
dsans@calidibio.com
For Investors:
Stephen Jasper
stephen@gilmartinir.com
Source: Calidi Biotherapeutics, Inc.